Geetika Srivastava

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease

Bart Barlogie, Frits van Rhee, John D. Shaughnessy et al. · Blood · 2008 · 102 citations · Full text

Medicine, Hematology, Oncology +8

Identification of pathologically insignificant prostate cancer is not accurate in unscreened men

Greg Shaw, B C Thomas, Sarah Dawson et al. · British Journal of Cancer · 2014 · 67 citations · Full text

Medicine, Oncology, Pathology +17

Prospective Multicenter Study of the Impact of Oncotype DX Colon Cancer Assay Results on Treatment Recommendations in Stage II Colon Cancer Patients

Geetika Srivastava, Lindsay A. Renfro, Robert J. Behrens et al. · The Oncologist · 2014 · 65 citations · Full text

Medicine, Oncology, Pathology +16

Risk of Intracranial Hemorrhage and Cerebrovascular Accidents in Non-small Cell Lung Cancer Brain Metastasis Patients

Geetika Srivastava, Vishal Rana, S. Wallace et al. · Journal of Thoracic Oncology · 2009 · 46 citations · Full text

Medicine, Neurosurgery, Oncology +14

Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma

Geetika Srivastava, Vishal Rana, Martha Q. Lacy et al. · Leukemia · 2013 · 33 citations · Full text

Medicine, Hematology, Oncology +15